重点通报！端午出行需求旺盛 滴滴打车顺风车订单量激增

端午出行需求旺盛 滴滴打车顺风车订单量激增

北京，2024年6月15日 - 据滴滴出行发布的数据，端午节当天，滴滴平台打车订单量同比增长37%，顺风车订单量同比增长超100%。其中，顺风车预约出行订单量同比去年增长278%，顺风车车主发布端午期间预约出行路线量同比去年上涨200%。

端午假期，人们出行需求旺盛，滴滴平台打车、顺风车订单量大幅增长。 其中，顺风车成为许多市民出行的首选方式。数据显示，济南、重庆、上海等城市成为端午热门预约目的地。

从跨城需求来看，北京至保定、石家庄、秦皇岛、天津等周边城市，山东省内济南至泰安/淄博、烟台至青岛，江苏省内南京至南通、泰州、扬州等，是今年端午的顺风车热门路线。 此外，不少用户选择携带宠物出行，预约滴滴顺风车携宠出行的订单量同比去年上涨43%。

滴滴出行表示，为保障用户假期出行安全，公司将加强对长距离、场站、经过高速/快速路订单的安全守护。 此外，滴滴还为用户提供了安全专线、110报警、亲友守护、驾驶行为反馈等丰富的安全工具。

专家指出，随着人们生活水平的提高，假期出行需求日益旺盛。即时配送平台应进一步提升服务质量，为用户提供更加安全、便捷的出行体验。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.